从临床研究到落地实施:荷兰缺血性卒中血管内治疗的路径
结果显示,MR CLEAN试验结果公布前EVT使用已显著增加(发病率比1.72,95%CI 1.46-2.04),公布后立即陡增后渐增(发病率比2.14,95%CI 1.77-2.59),2018年接受EVT的缺血性卒中患者比例增至5.8%。完善的基础设施、务实的临床实践方法及监管机构对国家循证指南的严格遵循促成了成功实施。
要点
- 2015年前EVT仅限少数中心选择性开展,2015年后基于多项临床试验的坚实证据成为国际指南推荐的标准治疗。
- MR CLEAN试验公布前EVT使用已显著增加(发病率比1.72),公布后立即陡增(发病率比2.14)。
- 2018年荷兰接受EVT的缺血性卒中患者比例增至5.8%。
核心结论
- 荷兰通过完善的基础设施、务实的临床实践方法及监管机构对国家循证指南的严格遵循,成功实现了EVT的落地实施。
主要发现
- 在MR CLEAN试验酝酿期,EVT患者缓慢增加,占所有缺血性卒中患者的0.2%。
- 试验结果正式公布前,每年EVT治疗患者数已呈统计学显著增加(发病率比1.72,95%CI 1.46-2.04)。
- 试验公布后,EVT使用立即陡增,随后逐渐增加(发病率比2.14,95%CI 1.77-2.59)。
- 2018年接受EVT的缺血性卒中患者比例增至5.8%。
临床怎么用
- 完善的基础设施、务实的临床实践方法及监管机构对国家循证指南的严格遵循可促进EVT的成功实施。
- 持续努力旨在进一步提高全国所有地区卒中患者接受EVT的比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment option. Based on limited evidence, it was performed in several dedicated stroke centers worldwide on selected patients. Since 2015, EVT for patients with intracranial large vessel occlusion has quickly been implemented as standard treatment in many countries worldwide, supported by the revised international guidelines based on solid evidence from multiple clinical trials. We describe the development in use of EVT in the Netherlands before, during, and after the pivotal EVT trials. We used data from all patients who were treated with EVT in the Netherlands from January 2002 until December 2018. We undertook a time-series analysis to examine trends in the use of EVT using Poisson regression analysis. Incidence rate ratios per year with 95% CIs were obtained to demonstrate the impact and implementation after the publication of the EVT trial results. We made regional observation plots, adjusted for stroke incidence, to assess the availability and use of the treatment in the country. In the buildup to the MR CLEAN (Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands), a slow increase of EVT patients was observed, with 0.2% of all ischemic stroke patients receiving EVT. Before the trial results were formally announced, a statistically significant increase in EVT-treated patients per year was observed (incidence rate ratio, 1.72 [95% CI, 1.46-2.04]), and after the trial publication, an immediate steep increase was seen, followed by a more gradual increase (incidence rate ratio, 2.14 [95% CI, 1.77-2.59]). In 2018, the percentage of ischemic stroke patients receiving EVT increased to 5.8%. A well-developed infrastructure, a pragmatic approach toward the use of EVT in clinical practice, in combination with a strict adherence by the regulatory authorities to national evidence-based guidelines has led to successful implementation of EVT in the Netherlands. Ongoing efforts are directed at further increasing the proportion of stroke patients with EVT in all regions of the country.
引用
- Wiegers EJA, Compagne KCJ, Janssen PM, et al. Path From Clinical Research to Implementation: Endovascular Treatment of Ischemic Stroke in the Netherlands. Stroke. 2020. PMID: 32568637. doi:10.1161/STROKEAHA.119.026731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。